Genprex rises as diabetes gene therapy shows promise in animal tests

Genprex

06/01/2026 12:41

** Shares of drug developer Genprex GNPX.O rise 7.8% to $1.94 premarket

** Co says its experimental gene therapy for diabetes, GPX-002, showed encouraging results in early animal studies

** Says therapy improved sugar processing; one primate in study normalized blood sugar after 7 months, another showed improvement but did not fully normalize sugar levels

** Mice normalized within 4 weeks - GNPX

** Co plans more animal studies and aims to seek regulatory nod for human trials

** As of last close, stock up ~3% over the past year

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))